Insect Cell, Per Se Patents (Class 435/348)
-
Publication number: 20140162296Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.Type: ApplicationFiled: March 14, 2013Publication date: June 12, 2014Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
-
Publication number: 20140161767Abstract: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.Type: ApplicationFiled: November 14, 2013Publication date: June 12, 2014Inventors: CAROLA LEUSCHNER, HECTOR ALILA, WILLIAM HANSEL
-
Publication number: 20140165219Abstract: Described are mutant Nav1.7 sodium channel alpha-subunits and nucleic acid sequences encoding such mutants. Further described are methods for characterizing a nucleic acid sequence that encodes a Nav1.7 sodium channel alpha-subunit, methods for determining a Nav1.7 haplotype, methods for determining a subject's predisposition to a neurologic disorder associated with a sodium channel mutation, and methods of identifying a compound that modulates mutant Nav1.7 sodium channels. Other materials, compositions, articles, devices, and methods relating to mutant Nav1.7 sodium channels are also described herein.Type: ApplicationFiled: August 14, 2013Publication date: June 12, 2014Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Mark F. Leppert, Nanda A. Singh
-
Publication number: 20140162936Abstract: The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X1)A(X2)(X3)(X4)(X5) (X6)LSFHKGEKFQIL(X7 (X8)(X9)(X10) (X11)(X12)G(X13)(X14)WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X1) is R, N, Q, E, K, H, S, T, C, or D; (X2) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X3) is R, T, H, N, K, S, C, N or Q; (X4) is S, W, T, C, N, Q, For Y; (X5) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X6) is D, Q, H, E, S, T, C, N, R or K; (X7) is D, N, R, E, Q, S, T, C, K or D; (X8) is M, W, G, F, A, S, T, C, S, N, Q, Y, V, L, I or P; (X9) is T, H, S, D, C, N, Q, R, K, E or absent; (X10) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X11) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X12) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X13) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X14) is W, Y, L, G, A, V, I, P, M, or F; (b)Type: ApplicationFiled: April 24, 2012Publication date: June 12, 2014Applicant: COVAGEN AGInventors: Simon Brack, Sarah Batey, Dragan Grabulovski, Julian Bertschinger, Daniel Schlatter, Jörg Benz, David Banner, Michael Hennig
-
Publication number: 20140162331Abstract: Disclosed are an amphipathic peptide-lipase conjugate with enhanced lipase activity, a polynucleotide coding for the conjugate, an expression vector carrying the polynucleotide, a transformant anchoring the expression vector therein, a method for preparing the conjugate, a lipolysis method using the conjugate, and a method for producing biodiesel using the lipase.Type: ApplicationFiled: August 10, 2012Publication date: June 12, 2014Inventors: Sun-Chang Kim, Bong Hyun Sung, Kyung Seok Yang, Jun Hyoung Lee, Ki Jung Lim, Myung Keun Park
-
Publication number: 20140165223Abstract: Described are methods and compositions for inhibiting the trimerization of ligands belonging to the TNF superfamily, in particular, inhibiting RANKL trimerization. Accordingly, the methods and compositions provided herein can be used to treat disorders associated with increased RANK signaling, in particular those related to bone loss. Compounds that inhibit trimerization of ligands belonging to the TNF superfamily are also described.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: B.S.R.C. "Alexander Fleming"Inventors: Eleni Ntouni, Georgios Kollias
-
Publication number: 20140163034Abstract: Nucleic acid and polypeptide sequences corresponding to FLAT, a partly cytosolic variant of the intracellular anandamide-degrading enzyme, fatty acid amide hydrolase-1 (FAAH-1), are provided. FLAT lacks amidase activity but binds the endocannibinoid anandamide and facilitates its transport into cells. A chemical scaffold for the inhibition of anandamide transport is identified. Compositions of the invention prevent anandamide internalization in vitro, interrupt anandamide deactivation in vivo, and cause profound CB1 cannabinoid receptor-mediated analgesia in a mouse model of inflammatory pain. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the modulation of anandamide transport would be of benefit.Type: ApplicationFiled: November 25, 2013Publication date: June 12, 2014Applicants: IIT-Istituto Italiano di Tecnologia, The Regents of the University of CaliforniaInventors: Daniele Piomelli, Jin Fu, Giovanni Bottegoni, Andrea Cavalli, Tiziano Bandiera
-
Transferases and Oxidoreductases, Nucleic Acids Encoding Them and Methods for Making and Using Them.
Publication number: 20140165221Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having transferase activity, e.g., transaminase activity, e.g., d-amino-acid transferase activity, and/or oxidoreductase activity, e.g., dehydrogenase activity, e.g., d-amino-acid dehydrogenase activity, and/or catalyze the transfer of a chemical group, catalyze transamination, catalyze the reaction: D-alanine+2-oxoglutarate<=>pyruvate+D-glutamate, and/or catalyze an oxidation-reduction reaction, catalyze the removal of hydrogen atoms, and/or catalyze the reaction: D-amino acid+H2O+acceptor<=>a 2-oxo acid+NH3+reduced acceptor.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: VERENIUM CORPORATIONInventors: DAVID P. WEINER, PETER LUGINBUHL, ANALIA BUENO, JOSLIN M. CUENCA, ERIN MARASCO -
Publication number: 20140155271Abstract: This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease.Type: ApplicationFiled: November 2, 2012Publication date: June 5, 2014Applicants: Population Diagnostics, Inc., The Research Foundation of State of University of New YorkInventors: ELI HATCHWELL, PEGGY S. EIS
-
Publication number: 20140154214Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.Type: ApplicationFiled: February 4, 2014Publication date: June 5, 2014Inventors: Bjarne Due LARSEN, Yvette Miata Petersen
-
Publication number: 20140155326Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 21, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Publication number: 20140155325Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 20, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Publication number: 20140154281Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.Type: ApplicationFiled: August 9, 2012Publication date: June 5, 2014Applicant: Onco Therapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
-
Publication number: 20140154752Abstract: Glycoside hydrolases having at least two different hydrolytic activities are provided. In one embodiment, an isolated recombinant hydrolase having at least two activities selected from a group including asparagine derivatives, glutamine derivatives, and histidine derivatives is provided. Further, a method of generating free sugars from a mixture comprising asparagine derivatives, glutamine derivatives, and histidine derivatives is provided.Type: ApplicationFiled: May 1, 2012Publication date: June 5, 2014Applicants: Sandia Corporation, The Regents of the University of CaliforniaInventors: Zhiwei Chen, Gregory D. Friedland, Swapnil R. Chhabra, Dylan C. Chivian, Blake A. Simmons
-
Publication number: 20140147453Abstract: The present invention relates to a fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhFas-1 domain which is the fourth fas-1 domain of ?ig-h3 lacking H1 and H2 regions; b) a MMP (Matrix metalloproteinase) substrate; and c) a peptide comprising RGD motif and an use thereof for preventing and treating inflammatory disease. The fusion peptide of the present invention inhibits expension of rheumatoid arthritis by adhesion and migration of sinoviocytes and may be used for preventing or treating inflammatory disease by inhibiting infiltration of immune cells.Type: ApplicationFiled: May 31, 2013Publication date: May 29, 2014Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Young Mo Kang, In San Kim, Jin Hee Kang, Keum Hee Sa
-
Publication number: 20140150137Abstract: The present invention relates to isolated polypeptides having endoglucanase activity, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.Type: ApplicationFiled: April 26, 2012Publication date: May 29, 2014Applicant: Novozymes, Inc.Inventors: Nikolaj Spodsberg, Brett McBrayer, Pierre Cassland
-
Publication number: 20140148575Abstract: The subject matter of the invention is an electroconducting nanowire, comprising an amyloid fibre which results from the self-assembling of peptides comprising a prion domain or a derivative of this domain and which is functionalized by electron transporting peptides, each comprising amino acids bound to one or more atoms of iron. Its subject matter is also a method of manufacturing this nanowire as well as the uses of said nanowire. Uses: manufacture of sensors for the detection of chemical or biological species, of nano-batteries, of radio-identification systems, of molecular memory systems, etc.Type: ApplicationFiled: March 6, 2012Publication date: May 29, 2014Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Vincent Forge, Christophe Horvath, Marc Fontecave, Nicolas Duraffourg
-
Publication number: 20140147458Abstract: The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient.Type: ApplicationFiled: February 24, 2012Publication date: May 29, 2014Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Geun Hee Kim, Shi Nae Kwon, Chan Hee Lee, Yeop Yoon
-
Publication number: 20140148355Abstract: The present invention relates to polypeptides that bind to H3K4 methylated chromatin, and in particular to the use of reagents comprising such polypeptides for epigenetic/epigenomic analysis.Type: ApplicationFiled: March 28, 2012Publication date: May 29, 2014Applicant: UNIVERSITY OF OSLOInventors: Reidunn B. Aalen, Tage Thorstensen, Rein Aasland, Verena Hoppmann
-
Publication number: 20140147893Abstract: The present invention relates to variants of alpha amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: July 6, 2012Publication date: May 29, 2014Applicant: NOVOZYMES A/SInventors: Tomoko Matsui, Aki Tomiki, Guillermo Coward-Kelly
-
Publication number: 20140148390Abstract: The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending moiety and the linker comprises a protease cleavage site. Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, cells expressing the Relaxin fusion polypeptides, pharmaceutical compositions and medical use of such fusion polypeptides.Type: ApplicationFiled: July 4, 2012Publication date: May 29, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ulrich Haupts, Andreas Wilmen
-
Publication number: 20140142164Abstract: The present invention relates to a vector including: (i) an inverted terminal repeat (ITR) nucleotide sequence at the 5? position; (ii) a nucleotide sequence functionally bonded to a promoter at the central position, said nucleotide sequence coding for a toxin; and (iii) an inverted terminal repeat (ITR) nucleotide sequence at the 3? position, wherein said vector does not include any viral nucleotide sequences of Junonia coenia densovirus other than the ITR sequences according to (i) and (iii). The present invention also relates to a method for producing recombinant and nonreplicative particles of Junonia coenia densovirus (JcDNV) using such a vector. Finally, the present invention relates to the use of recombinant and nonreplicative particles of Junonia coenia densovirus produced according to the above-described method as a moth-control agent.Type: ApplicationFiled: November 2, 2011Publication date: May 22, 2014Inventors: Mylene Ogliastro, Aurelie Perrin, Max Bergoin, Francois Cousserans, Philippe Fournier
-
Publication number: 20140141444Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
-
Publication number: 20140141491Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes having isomerase activity, e.g., racemase activity, e.g., amino acid racemase activity, alanine racemase activity, and/or epimerase activity, and/or catalyze the re-arrangement of atoms within a molecule, catalyze the conversion of one isomer into another, catalyze the conversion of an optically active substrate into a raceme, which is optically inactive, catalyze the interconversion of substrate enantiomers, catalyze the stereochemical inversion around the asymmetric carbon atom in a substrate having only one center of asymmetry, catalyze the stereochemical inversion of the configuration around an asymmetric carbon atom in a substrate having more than one asymmetric center, and/or catalyze the racemization of amino acids.Type: ApplicationFiled: August 14, 2013Publication date: May 22, 2014Applicant: Verenium CorporationInventors: David P. WEINER, Ellen G. BURKE, Peter LUGINBUHL, Analia BUENO, Joslin M. CUENCA, Mervyn L. DE SOUZA, Sherry KOLLMANN
-
Publication number: 20140141445Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
-
Publication number: 20140142046Abstract: The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and/or promoting muscle hypertrophy and growth.Type: ApplicationFiled: January 11, 2012Publication date: May 22, 2014Applicant: FATE THERAPEUTICS, INC.Inventors: Tom Tong Lee, Monica Hayhurst Bennett, Michael J. Fitch, Peter Flynn
-
Publication number: 20140140978Abstract: The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.Type: ApplicationFiled: June 15, 2012Publication date: May 22, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE PARIS SUD-PARIS XI, INRA (Institut National de la Recherche Agronomique)Inventors: David Machover, Pascal Bonnarme
-
Publication number: 20140141508Abstract: Recombinant carrier molecules having amino acid sequences from thermostable enzymes and methods of use for expression, recovery and delivery of foreign sequences (peptides and polypeptides) produced in different systems (bacteria, yeast, DNA, cell cultures such as mammalian, plant, insect cell cultures, protoplast and whole plants in vitro or in vivo are provided. The recombinant carrier molecule using sequences from lichenase B (Lic B) were also made and used as part of carrier protein to express, recover and deliver a variety of target polypeptides of interest.Type: ApplicationFiled: October 23, 2013Publication date: May 22, 2014Applicant: iBio, Inc.Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuk
-
Publication number: 20140134722Abstract: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.Type: ApplicationFiled: June 17, 2010Publication date: May 15, 2014Inventor: Alexey Ryazanov
-
Publication number: 20140134736Abstract: The present disclosure relates to methods of controlling the sulfide (S2˜) content in systems, such as oil and gas reservoirs and pipelines, by the use of chlorine oxyanions and microorganisms with (per)chlorate-reducing activity.Type: ApplicationFiled: May 31, 2012Publication date: May 15, 2014Applicant: The Regents of the University of CaliforniaInventor: John D. Coates
-
Publication number: 20140135382Abstract: Methods and compositions are used to identify and characterize new channelrhodopsins derived from algae and several of which are red-shifted. The rhodopsin domain of these red-shifted channelrhodopsins can be cloned and expressed in mammalian systems and used in optogenetic applications and as therapeutic agents. Also provided are methods and compositions for use in red-shifting the absorbance maxima of channelrhodopsins in order to improve their utility for use in vivo.Type: ApplicationFiled: October 14, 2013Publication date: May 15, 2014Applicant: Board of Regents of the University of Texas SystemInventors: John Lee SPUDICH, Elena G. GOVORUNOVA, Oleg A. SINESHCHEKOV
-
Patent number: 8722363Abstract: The invention features isolated cytochrome P450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds.Type: GrantFiled: May 3, 2013Date of Patent: May 13, 2014Assignee: University of Kentucky Research FoundationInventor: Lyle F. Ralston
-
Patent number: 8722401Abstract: A method for the in vitro production of a cell population P? from a cell population P, the production requiring the presence of at least one factor which is expressed by feeder cells, wherein a) feeder cells proliferate at a temperature T1, b) proliferated feeder cells are contacted with the cell population P, c) the cell mixture obtained at step (b) is cultivated at a temperature T2 which is chosen such that the cell population P proliferates and the feeder cells do not proliferate, the at least one factor being expressed by the feeder cells, and d) the cell population P? so produced is recovered. Advantageously, the production consists in an expansion, the feeder cells are insect feeder cells and the cell population P to be expanded is a T lymphocyte population, preferably a Trl lymphocyte population.Type: GrantFiled: April 18, 2006Date of Patent: May 13, 2014Assignees: TxCell, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Hervé Groux, Françoise Cottrez, Hervé Bastian, Valérie Brun
-
Publication number: 20140127174Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: January 7, 2014Publication date: May 8, 2014Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne D. Larsen, Jens R. Daugaard, Trine S. R. Neerup
-
Publication number: 20140127801Abstract: The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Applicant: uniQure IP B.V.Inventors: Andrew Christian BAKKER, Wilhelmus Theodorus Johannes Maria Christiaan Maria Christ HERMENS, Yvet NOORDMAN
-
Publication number: 20140127759Abstract: A ?-glucosidase exhibits high activity in the presence of biomass and has high thermal stability compared to conventional enzymes. The ?-glucosidase includes substitutions and/or deletions of amino acids, at least three amino acids selected from the group consisting of Glu39, Asp169, Arg170, Arg220, Tyr227, and Glu330, of the parent ?-glucosidase with other amino acids and exhibits a decomposition activity.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Toray Industries, Inc.Inventors: Hiroyuki Kurihara, Katsushige Yamada, Kazuhiko Ishikawa, Yumiko Mishima, Yasunobu Wada, Yuji Kado
-
Publication number: 20140127246Abstract: It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4+ and cytolytic CD8+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Bira Arya, Vladimir L. Larionov
-
Publication number: 20140127175Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.Type: ApplicationFiled: January 7, 2014Publication date: May 8, 2014Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
-
Publication number: 20140127216Abstract: An expression cassette, wherein said expression cassette comprises: (a) an ie 1 promoter from white spot syndrome virus or a variant thereof; (b) a nucleic acid sequence encoding an N-terminal gp64 signal peptide or variant thereof, a nucleic acid sequence encoding an antigenic peptide, a nucleic acid encoding a transmembrane region, and a nucleic acid encoding a gp64 cytoplasmic region or variant thereof; in which the promoter is operably linked to the nucleic acid sequence.Type: ApplicationFiled: February 8, 2012Publication date: May 8, 2014Applicant: Temasek Life Sciences Laboratory LimitedInventors: Premanand Balraj, Hwei-Sing Jimmy Kwang, Anbu Kumar Karuppannan
-
Publication number: 20140127750Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosyl donor and a galactosyl acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor.Type: ApplicationFiled: December 12, 2013Publication date: May 8, 2014Applicant: CORNELL UNIVERSITYInventors: Ralph L. OBENDORF, Takashi UEDA
-
Patent number: 8716232Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: GrantFiled: July 10, 2013Date of Patent: May 6, 2014Assignee: University of Pittsburgh— of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Publication number: 20140120588Abstract: Improving wild nitrile hydratase enables the provision of a protein which has nitrile hydratase activity and which has further improved heat resistance, amide compound resistance and high temperature accumulation properties. Use protein (A) or (B), (A) being a protein characterised by having nitrile hydratase activity and by including an amino acid sequence in which a specific amino acid residue in an amino acid sequence in wild nitrile hydratase has been substituted by another amino acid residue, and (B) being a protein characterised by having nitrile hydratase activity and by including an amino acid sequence in which one or several amino acid residues in the amino acid sequence of protein (A), other than the abovementioned specific amino acid residue, is deleted, substituted and/or added.Type: ApplicationFiled: May 30, 2012Publication date: May 1, 2014Applicant: Mitsubishi Rayon Co., Ltd.Inventors: Fumiaki Watanabe, Takanori Ambo, Ai Hara
-
Publication number: 20140120099Abstract: The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.Type: ApplicationFiled: September 24, 2013Publication date: May 1, 2014Applicants: UCL Business PLC, Ludwig Institute for Cancer ResearchInventors: Ivan Nemazanyy, Ganna Panasyuk, Alexander Zhyvoloup, Michael Waterfield, Ivan Gout
-
Publication number: 20140120085Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.Type: ApplicationFiled: September 25, 2013Publication date: May 1, 2014Applicant: BioNTech AGInventors: Özlem TÜRECI, Ugur SAHIN, Sandra SCHNEIDER, Gerd HELFTENBEIN, Volker SCHLÜTER, Dirk USENER, Philippe THIEL, Michael KOSLOWSKI
-
Patent number: 8709775Abstract: Provided are hydrolases, including lipases, saturases, palmitases and/or stearatases, and polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. Further provided are polypeptides, e.g., enzymes, having a hydrolase activity, e.g., lipases, saturases, palmitases and/or stearatases and methods for preparing low saturate or low trans fat oils, such as low saturate or low trans fat animal or vegetable oils, e.g., soy or canola oils.Type: GrantFiled: August 28, 2009Date of Patent: April 29, 2014Assignee: DSM IP Assets B.V.Inventors: Nelson R. Barton, Analia Bueno, Joslin G. Cuenca, Tim S. Hitchman, Katie A. Kline, Jonathan D. Lyon, Mark L. Miller, Mark A. Wall, Christopher L. G. Dayton
-
Publication number: 20140113352Abstract: The present invention provides compositions and methods for the expression of recombinant ?-glucosidase variants, as well as their use in the production of fermentable sugars from cellulosic biomass.Type: ApplicationFiled: December 19, 2013Publication date: April 24, 2014Applicant: Codexis, Inc.Inventors: Dipnath Baidyaroy, Louis Clark, Lisa M. Newman
-
Publication number: 20140113335Abstract: This invention provides novel variant cellulolytic enzymes having improved activity and/or stability. In certain embodiments the variant cellulotyic enzymes comprise a glycoside hydrolase with or comprising a substitution at one or more positions corresponding to one or more of residues F64, A226, and/or E246 in Thermobifida fusca Cel9A enzyme. In certain embodiments the glycoside hydrolase is a variant of a family 9 glycoside hydrolase. In certain embodiments the glycoside hydrolase is a variant of a theme B family 9 glycoside hydrolase.Type: ApplicationFiled: April 11, 2012Publication date: April 24, 2014Applicant: Novozymes A/SInventors: Robert Blazej, Nicholas Toriello, Charles Emrich, Richard N. Cohen, Nitzan Koppel
-
Publication number: 20140115740Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: December 13, 2013Publication date: April 24, 2014Applicants: Novozymes, Inc., Novozymes A/SInventors: Lan Tang, Ye Liu, Junxin Duan, Yu Zhang, Christian Isak Jorgensen, Randall Kramer
-
Publication number: 20140115739Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: October 11, 2013Publication date: April 24, 2014Inventors: Suchindra Maiyuran, Randall Kramer, Paul Harris
-
Publication number: 20140113336Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: August 1, 2012Publication date: April 24, 2014Inventor: Nikolaj Spodsberg